Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis

Karen S. McCoy, Alexandra Quittner, Christopher M. Oermann, Ronald L. Gibson, George Z. Retsch-Bogart, A. Bruce Montgomery

Research output: Contribution to journalArticle

262 Citations (Scopus)

Abstract

Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. Objectives: To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF. Methods: After randomization and a 28-day course of tobramycin inhalation solution (TIS), patients (n = 211; ≥6yr; ≥3 TIS courses within previous year; FEV1 ≥25% and ≤75% predicted values) were treated with 75 mg AZLI or placebo, twice or three times daily for 28 days, then monitored for 56 days. The primary efficacy endpoint was time to need for additional inhaled or intravenous antipseudomonal antibiotics. Secondary endpoints included changes in respiratory symptoms (CF Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function (FEV1), and sputum PA density. Adverse events andminimum inhibitory concentrations of aztreonam for PA were monitored. Measurements and Main Results: AZLI treatment increased median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation by 21 days, compared with placebo (AZLI, 92 d; placebo, 71 d; P = 0.007). AZLI improved mean CFQ-R respiratory scores (5.01 points, P = 0.02), FEV1 (6.3%, P = 0.001), and sputum PA density (20.66 log 10 cfu/g, P = 0.006) compared with placebo; no AZLI dose-response was observed. Adverse events reported for AZLI and placebo were comparable and consistent with CF lung disease. Susceptibility of PA to aztreonam at baseline and end of therapy were similar. Conclusions: AZLI was effective in patients with CF using frequent TIS therapy. AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).

Original languageEnglish
Pages (from-to)921-928
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume178
Issue number9
DOIs
StatePublished - Nov 1 2008

Fingerprint

Aztreonam
Cystic Fibrosis
Pseudomonas aeruginosa
Lysine
Inhalation
Placebos
Tobramycin
Anti-Bacterial Agents
Sputum
Lung
Safety
Respiratory Therapy
Pseudomonas Infections
Random Allocation
Lung Diseases

Keywords

  • Aztreonam
  • Cystic fibrosis
  • Inhaled antibiotics
  • Patient-reported outcomes
  • Pseudomonas
  • Respiratory symptoms

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

McCoy, K. S., Quittner, A., Oermann, C. M., Gibson, R. L., Retsch-Bogart, G. Z., & Montgomery, A. B. (2008). Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 178(9), 921-928. https://doi.org/10.1164/rccm.200712-1804OC

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. / McCoy, Karen S.; Quittner, Alexandra; Oermann, Christopher M.; Gibson, Ronald L.; Retsch-Bogart, George Z.; Montgomery, A. Bruce.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 178, No. 9, 01.11.2008, p. 921-928.

Research output: Contribution to journalArticle

McCoy, KS, Quittner, A, Oermann, CM, Gibson, RL, Retsch-Bogart, GZ & Montgomery, AB 2008, 'Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis', American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 9, pp. 921-928. https://doi.org/10.1164/rccm.200712-1804OC
McCoy, Karen S. ; Quittner, Alexandra ; Oermann, Christopher M. ; Gibson, Ronald L. ; Retsch-Bogart, George Z. ; Montgomery, A. Bruce. / Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. In: American Journal of Respiratory and Critical Care Medicine. 2008 ; Vol. 178, No. 9. pp. 921-928.
@article{aa08a322f4b644ba95c53c7473845e30,
title = "Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis",
abstract = "Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. Objectives: To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF. Methods: After randomization and a 28-day course of tobramycin inhalation solution (TIS), patients (n = 211; ≥6yr; ≥3 TIS courses within previous year; FEV1 ≥25{\%} and ≤75{\%} predicted values) were treated with 75 mg AZLI or placebo, twice or three times daily for 28 days, then monitored for 56 days. The primary efficacy endpoint was time to need for additional inhaled or intravenous antipseudomonal antibiotics. Secondary endpoints included changes in respiratory symptoms (CF Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function (FEV1), and sputum PA density. Adverse events andminimum inhibitory concentrations of aztreonam for PA were monitored. Measurements and Main Results: AZLI treatment increased median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation by 21 days, compared with placebo (AZLI, 92 d; placebo, 71 d; P = 0.007). AZLI improved mean CFQ-R respiratory scores (5.01 points, P = 0.02), FEV1 (6.3{\%}, P = 0.001), and sputum PA density (20.66 log 10 cfu/g, P = 0.006) compared with placebo; no AZLI dose-response was observed. Adverse events reported for AZLI and placebo were comparable and consistent with CF lung disease. Susceptibility of PA to aztreonam at baseline and end of therapy were similar. Conclusions: AZLI was effective in patients with CF using frequent TIS therapy. AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).",
keywords = "Aztreonam, Cystic fibrosis, Inhaled antibiotics, Patient-reported outcomes, Pseudomonas, Respiratory symptoms",
author = "McCoy, {Karen S.} and Alexandra Quittner and Oermann, {Christopher M.} and Gibson, {Ronald L.} and Retsch-Bogart, {George Z.} and Montgomery, {A. Bruce}",
year = "2008",
month = "11",
day = "1",
doi = "10.1164/rccm.200712-1804OC",
language = "English",
volume = "178",
pages = "921--928",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis

AU - McCoy, Karen S.

AU - Quittner, Alexandra

AU - Oermann, Christopher M.

AU - Gibson, Ronald L.

AU - Retsch-Bogart, George Z.

AU - Montgomery, A. Bruce

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. Objectives: To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF. Methods: After randomization and a 28-day course of tobramycin inhalation solution (TIS), patients (n = 211; ≥6yr; ≥3 TIS courses within previous year; FEV1 ≥25% and ≤75% predicted values) were treated with 75 mg AZLI or placebo, twice or three times daily for 28 days, then monitored for 56 days. The primary efficacy endpoint was time to need for additional inhaled or intravenous antipseudomonal antibiotics. Secondary endpoints included changes in respiratory symptoms (CF Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function (FEV1), and sputum PA density. Adverse events andminimum inhibitory concentrations of aztreonam for PA were monitored. Measurements and Main Results: AZLI treatment increased median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation by 21 days, compared with placebo (AZLI, 92 d; placebo, 71 d; P = 0.007). AZLI improved mean CFQ-R respiratory scores (5.01 points, P = 0.02), FEV1 (6.3%, P = 0.001), and sputum PA density (20.66 log 10 cfu/g, P = 0.006) compared with placebo; no AZLI dose-response was observed. Adverse events reported for AZLI and placebo were comparable and consistent with CF lung disease. Susceptibility of PA to aztreonam at baseline and end of therapy were similar. Conclusions: AZLI was effective in patients with CF using frequent TIS therapy. AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).

AB - Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonas aeruginosa (PA) airway infection was evaluated in this randomized, double-blind, placebo-controlled study. Objectives: To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF. Methods: After randomization and a 28-day course of tobramycin inhalation solution (TIS), patients (n = 211; ≥6yr; ≥3 TIS courses within previous year; FEV1 ≥25% and ≤75% predicted values) were treated with 75 mg AZLI or placebo, twice or three times daily for 28 days, then monitored for 56 days. The primary efficacy endpoint was time to need for additional inhaled or intravenous antipseudomonal antibiotics. Secondary endpoints included changes in respiratory symptoms (CF Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function (FEV1), and sputum PA density. Adverse events andminimum inhibitory concentrations of aztreonam for PA were monitored. Measurements and Main Results: AZLI treatment increased median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation by 21 days, compared with placebo (AZLI, 92 d; placebo, 71 d; P = 0.007). AZLI improved mean CFQ-R respiratory scores (5.01 points, P = 0.02), FEV1 (6.3%, P = 0.001), and sputum PA density (20.66 log 10 cfu/g, P = 0.006) compared with placebo; no AZLI dose-response was observed. Adverse events reported for AZLI and placebo were comparable and consistent with CF lung disease. Susceptibility of PA to aztreonam at baseline and end of therapy were similar. Conclusions: AZLI was effective in patients with CF using frequent TIS therapy. AZLI delayed time to need for inhaled or intravenous antipseudomonal antibiotics, improved respiratory symptoms and pulmonary function, and was well tolerated. Clinical trial registered with www.clinicaltrials.gov (NCT 00104520).

KW - Aztreonam

KW - Cystic fibrosis

KW - Inhaled antibiotics

KW - Patient-reported outcomes

KW - Pseudomonas

KW - Respiratory symptoms

UR - http://www.scopus.com/inward/record.url?scp=55549137086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549137086&partnerID=8YFLogxK

U2 - 10.1164/rccm.200712-1804OC

DO - 10.1164/rccm.200712-1804OC

M3 - Article

C2 - 18658109

AN - SCOPUS:55549137086

VL - 178

SP - 921

EP - 928

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -